Twynsta

Twynsta is a brand name of amlodipine/telmisartan, approved by the FDA in the following formulation(s):

TWYNSTA (amlodipine besylate; telmisartan - tablet; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: October 16, 2009
  
  Strength(s): EQ 10MG BASE;40MG, EQ 10MG BASE;80MG ^[RLD], EQ 5MG BASE;40MG, EQ 5MG BASE;80MG
  

Has a generic version of Twynsta been approved?

No. There is currently no therapeutically equivalent version of Twynsta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Twynsta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Benzimidazoles useful as angiotensin-11 antagonists
  Patent 5,591,762
  Issued: January 7, 1997
  Inventor(s): Hauel; Norbert & Narr, deceased; Berthold & Ries; Uwe & van Meel; Jacobus C. A. & Wienen; Wolfgang & Entzeroth; Michael
  Assignee(s): Dr. Karl Thomae GmbH
  Disclosed herein are angiotensin-II antagonists of the formula ##STR1## wherein R.sub.1 is, other than hydrogen and, inter alia, halogen, lower alkyl or cycloalkyl; R.sub.2 is, inter alia, optionally substituted benzimidazol-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl, butanesultam-1-yl, imidazol-4-yl, and tetrahydobenzimidazol-2-yl; R.sub.3 is, inter alia, lower alkyl; and, R.sub.4 is an acidic group, such as carboxyl or tetrazolyl. An exemplary compound is: (a) 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)-benzimidazol-1-yl] methyl]-biphenyl-2-carboxylic acid.
  
  Patent expiration dates:
  
  
  • January 7, 2014
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 16, 2012 - NEW COMBINATION
  
  

See also...

• Twynsta Consumer Information (Drugs.com)
• Twynsta Consumer Information (Wolters Kluwer)
• Twynsta Consumer Information (Cerner Multum)
• Twynsta Advanced Consumer Information (Micromedex)
• Telmisartan/Amlodipine Consumer Information (Wolters Kluwer)
• Amlodipine and telmisartan Consumer Information (Cerner Multum)
• Telmisartan and amlodipine Advanced Consumer Information (Micromedex)